2023
DOI: 10.1007/s00417-023-06036-x
|View full text |Cite|
|
Sign up to set email alerts
|

Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration

Abstract: What was known・A high incidence of intraocular inflammation (IOI) after intravitreal brolucizumab (IVBr) administration has been reported, and occlusive vasculitis, which can be associated with vision loss, has been considered as a severe phenotype of IOI.・The risk factors of IVBr-associated IOI have not been fully elucidated. What this study adds・After IVBr administration as switching therapy for nAMD, 18 (20.6%) eyes developed IOI and 2 (2.3%) exhibited retinal artery occlusion. ・Macular atrophy and subretin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 35 publications
0
5
0
Order By: Relevance
“…Choroidal thinning caused by IVBr has also been reported [9][10][11][12][13]. However, to our knowledge, no reported cases exist of severe choroidal thinning caused by IOI after IVBr.…”
Section: Introductionmentioning
confidence: 80%
See 3 more Smart Citations
“…Choroidal thinning caused by IVBr has also been reported [9][10][11][12][13]. However, to our knowledge, no reported cases exist of severe choroidal thinning caused by IOI after IVBr.…”
Section: Introductionmentioning
confidence: 80%
“…Several reports have documented IOI associated with brolucizumab, with reported frequencies ranging from 4.6 to 22.1% [2,[5][6][7][8][9][10][11]. According to reports, the Japanese may have a higher incidence of IOI [5,[7][8][9][10][11]. Most reported cases of IOI have focused on anterior chamber inflammation, retinal vasculitis, and retinal vascular occlusion, with no reports specifically addressing the choroid.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…29 Most eyes treated with brolucizumab in the real world were previously treated with other anti-VEGF agents. 16,17,[21][22][23]26,35,[39][40][41][42][43] It is possible that previously treated eyes are equally susceptible to IOI but somehow less susceptible to retinal vasculitis than treatment-naïve eyes.…”
Section: Safetymentioning
confidence: 99%